Archive

Metabolic hormone ‘leptin’ linked to poor vaccine response

Written by Charlie King | 15 Jun 2021

Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found. The… read more.

FDA approves Tembexa for smallpox – Chimerix

Written by Charlie King | 14 Jun 2021

Chimerix announced that the FDA has granted Tembexa (brincidofovir) tablets and oral suspension approval for the treatment of smallpox. Tembexa is approved for adult and pediatric patients, including… read more.

Liraglutide prevents accumulation of lipid linked to cardiac mortality

Written by Charlie King | 14 Jun 2021

Researchers at the Karolinska Institutet, University of Oxford and University of Copenhagen have shown that elevated levels of lipids known as ceramides can be associated with a ten-fold… read more.

Liminal BioSciences announces FDA approval for its BLA of Ryplazim to treat patients with plasminogen deficiency type 1

Written by Charlie King | 13 Jun 2021

Liminal BioSciences Inc. announced that the FDA has approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics… read more.

Simple diagnostic tool predicts individual risk of Alzheimer’s

Written by Charlie King | 13 Jun 2021

Researchers at Lund University in Sweden have developed an algorithm that combines data from a simple blood test and brief memory tests, to predict with great accuracy who… read more.

Janssen presents results of first head-to-head study of biologic therapies in patients with moderate to severe Crohn’s disease

Written by Charlie King | 12 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced efficacy and safety data for Stelara (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),including data from the SEAVUE… read more.

Testosterone therapy may reduce non-alcoholic fatty liver disease in obese

Written by Charlie King | 12 Jun 2021

According to a new study, testosterone therapy may reduce non-alcoholic fatty liver disease in obese men with functional hypogonadism and type-2 diabetes. Testosterone therapy may help obese men… read more.

Seagen announces long-term results from Tukysa pivotal trial for HER2-positive breast cancer during the 2021 ASCO Annual Meeting

Written by Charlie King | 11 Jun 2021

Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of… read more.

An illuminating possibility for stroke treatment: Nano-photosynthesis

Written by Charlie King | 11 Jun 2021

Blocked blood vessels in the brains of stroke patients prevent oxygen-rich blood from getting to cells, causing severe damage. Plants and some microbes produce oxygen through photosynthesis. What… read more.

FDA approves Lumakras the first and only targeted treatment for KRAS G12C-mutated locally advanced or metastatic NSCLC – Amgen

Written by Charlie King | 10 Jun 2021

Amgen has announced that the FDA has approved Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC),… read more.

Implantable piezoelectric polymer improves controlled release of drugs

Written by Charlie King | 10 Jun 2021

Repeated tests showed a similar amount of drug release per activation, confirming robust control of release rate. A membrane made from threads of a polymer commonly used in… read more.

Testing and using drug treatment during a pandemic

Written by Christine Clark | 10 Jun 2021

Interview and article by Christine Clark. Steve Kirsch, CEO of the Covid-19 Early Treatment Fund (CETF) explains how a study in Nepal will advance our understanding of effective… read more.

« Previous 1 … 34 35 36 37 38 … 63 Next »

Archive

Subscribe for our mailing list

Follow Us